Key result
Atrial septostomy combined with PAH-specific pharmacotherapy improved median survival compared to atrial septostomy alone (83 vs 53 months; p=0.010).
Why the study?
Does atrial septostomy combined with PAH-specific pharmacotherapy improve survival compared to atrial septostomy alone in patients with severe pulmonary arterial hypertension?
Cohort (n=34)
Does atrial septostomy combined with PAH-specific pharmacotherapy improve survival compared to atrial septostomy alone in patients with severe pulmonary arterial hypertension?
Absolute Event Rate: 83% vs 53%
p-value: p=0.010
In patients with severe pulmonary arterial hypertension, atrial septostomy is a safe palliative intervention, and long-term survival is significantly improved when it is combined with PAH-specific pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
May support combined therapy in severe PAH; hypothesis-generating and requires randomized confirmation.
Sandoval et al. (2011) conducted a cohort in severe pulmonary arterial hypertension (n=34). Atrial septostomy combined with PAH-specific pharmacotherapy vs. Atrial septostomy alone was evaluated on Median survival (p=0.010). Atrial septostomy combined with PAH-specific pharmacotherapy improved median survival compared to atrial septostomy alone (83 vs 53 months; p=0.010).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: